Brokers Issue Forecasts for ALX Oncology Holdings Inc.’s Q1 2024 Earnings (NASDAQ:ALXO)
ALX Oncology Holdings Inc. (NASDAQ:ALXO – Free Report) – Equities researchers at HC Wainwright boosted their Q1 2024 earnings estimates for shares of ALX Oncology in a research report issued on Monday, March 11th. HC Wainwright analyst S. Ramakanth now forecasts that the company will earn ($0.78) per share for the quarter, up from their prior estimate of ($0.83). The consensus estimate for ALX Oncology’s current full-year earnings is ($3.40) per share. HC Wainwright also issued estimates for ALX Oncology’s Q2 2024 earnings at ($0.72) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.62) EPS, FY2024 earnings at ($2.80) EPS, Q1 2025 earnings at ($0.60) EPS, Q2 2025 earnings at ($0.57) EPS, Q3 2025 earnings at ($0.55) EPS, Q4 2025 earnings at ($0.45) EPS and FY2025 earnings at ($2.16) EPS.
ALXO has been the topic of several other reports. Jefferies Financial Group raised shares of ALX Oncology from a “hold” rating to a “buy” rating and increased their target price for the stock from $8.00 to $18.00 in a research note on Friday, December 8th. Stifel Nicolaus reissued a “hold” rating and set a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research note on Friday, March 8th. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, ALX Oncology currently has an average rating of “Moderate Buy” and a consensus target price of $18.42.
View Our Latest Stock Analysis on ALX Oncology
ALX Oncology Trading Down 3.9 %
Shares of NASDAQ ALXO opened at $11.15 on Thursday. The company has a debt-to-equity ratio of 0.05, a quick ratio of 5.24 and a current ratio of 5.24. ALX Oncology has a 52-week low of $3.94 and a 52-week high of $17.42. The firm has a 50 day moving average price of $14.59 and a two-hundred day moving average price of $10.62. The stock has a market cap of $559.19 million, a P/E ratio of -2.97 and a beta of 1.63.
Insider Transactions at ALX Oncology
In related news, CAO Shelly Pinto sold 2,717 shares of ALX Oncology stock in a transaction on Thursday, January 4th. The shares were sold at an average price of $13.60, for a total value of $36,951.20. Following the transaction, the chief accounting officer now directly owns 78,591 shares of the company’s stock, valued at $1,068,837.60. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Company insiders own 50.30% of the company’s stock.
Hedge Funds Weigh In On ALX Oncology
A number of hedge funds have recently bought and sold shares of the company. Vanguard Group Inc. increased its position in shares of ALX Oncology by 49.0% during the 4th quarter. Vanguard Group Inc. now owns 1,502,409 shares of the company’s stock valued at $22,371,000 after purchasing an additional 494,173 shares during the last quarter. Wellington Management Group LLP purchased a new stake in shares of ALX Oncology during the 4th quarter valued at about $1,201,000. American International Group Inc. increased its position in shares of ALX Oncology by 24.1% during the 4th quarter. American International Group Inc. now owns 13,398 shares of the company’s stock valued at $199,000 after purchasing an additional 2,600 shares during the last quarter. Price T Rowe Associates Inc. MD purchased a new stake in shares of ALX Oncology during the 4th quarter valued at about $8,090,000. Finally, Legal & General Group Plc increased its position in shares of ALX Oncology by 42.6% during the 4th quarter. Legal & General Group Plc now owns 2,289 shares of the company’s stock valued at $34,000 after purchasing an additional 684 shares during the last quarter. Institutional investors own 83.37% of the company’s stock.
About ALX Oncology
ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. Its lead product candidate is evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes, acute myeloid leukemia, head and neck squamous cell carcinoma, gastric/gastroesophageal junction, and breast cancer.
Featured Articles
Receive News & Ratings for ALX Oncology Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for ALX Oncology and related companies with MarketBeat.com’s FREE daily email newsletter.
